MGD014 / MacroGenics - LARVOL DELTA

The DART DELIVER-02 Study (clinicaltrials.gov) - P1 | N=24 | Suspended | Sponsor: University of North Carolina, Chapel Hill | Recruiting ➔ Suspended

Trial suspension • Human Immunodeficiency Virus • Infectious Disease

The DART DELIVER-02 Study (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: University of North Carolina, Chapel Hill

New P1 trial • Human Immunodeficiency Virus • Infectious Disease

A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: MacroGenics | Active, not recruiting ➔ Completed | N=54 ➔ 24

Combination therapy • Enrollment change • Trial completion • Human Immunodeficiency Virus • Infectious Disease • CD4

A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy (clinicaltrials.gov) - P1 | N=54 | Active, not recruiting | Sponsor: MacroGenics | Recruiting ➔ Active, not recruiting

Combination therapy • Enrollment closed • Human Immunodeficiency Virus • Infectious Disease • CD4

A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: MacroGenics | Trial completion date: Jul 2023 ➔ Mar 2024 | Trial primary completion date: Jul 2023 ➔ Mar 2024

Combination therapy • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4 • IL10 • IL2 • IL5 • IL6

A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: MacroGenics | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Human Immunodeficiency Virus • Immunology • Infectious Disease • CD4 • IL10 • IL2 • IL5 • IL6

In vivo preclinical efficacy of MGD014 and MGD020 (HIV-1 envelope x CD3 DART molecules) and first-in-human phase 1 clinical safety evaluation of MGD014 (AIDS 2022) - P1 | "Administration of MGD020+MGD014 mediated greater HIV-1 clearance activity than individual DART molecules in HIV-1-infected humanized mice. MGD014 was well-tolerated in PWH on ART. A first-in-human study with MGD020+MGD014 in PWH on ART will begin in 2022.Our data support future clinical studies combining DART molecules and latency reversing agents."

P1 data • Preclinical • Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8

A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy (clinicaltrials.gov) - P1 | N=54 | Not yet recruiting | Sponsor: MacroGenics

Combination therapy • New P1 trial • Human Immunodeficiency Virus • Immunology • Infectious Disease • CD4 • IFNG • IL10 • IL2 • IL5 • IL6 • TNFA

MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy (clinicaltrials.gov) - P1; N=24; Completed; Sponsor: MacroGenics; Recruiting ➔ Completed

Clinical • Trial completion • Human Immunodeficiency Virus • Immunology • Infectious Disease • CD4

MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy (clinicaltrials.gov) - P1; N=26; Recruiting; Sponsor: MacroGenics; Trial completion date: Mar 2020 ➔ Oct 2021

Trial completion date • Human Immunodeficiency Virus • Immunology • Infectious Disease